On March 13th, 2020 the Pharma index on National Stock Exchange made a low of 6242.85 since from that day the pharmaceutical stock has given a tremendous return. The pharma index made a high of 14282.90 an up move of 8040.05 points with almost 40% returns in 1 year and it has been assumed that the future outlook of the Indian Pharmaceutical industry will have a 3 times growth from till next decade. Indian domestic market is estimated to grow around US$ 41 billion by 2021 and may reach US$ 65 billion by 2024.These growth figures indicate that in long term the pharma sector can be a game-changer for the investors along with a great contribution to the countries economy. We are the major suppliers of generic medicines & drugs across the globe and with new PLI schemes and government intervention for 100% FDI the pharmaceutical industry will witness new growth ahead in the future. The contribution of around 1.72 % to the GDP of the country, makes a significant mark. Earlier it was only 1% in last decade. Lots of research& development programs, FDI inflow opens new avenues for the industry to grow further. The flow of $ 16.5 billion by FDI in April 2000-June 2020, due to 100% FDI is approval in greenfield projects via automatic route & 74 % FDI for brownfield projects. The efforts made by pharmaceutical companies to overcome the current Covid-19 crisis with the help of the Indian government show the robustness itself. We are the largest manufacturer of vaccines across the globe, and the fight against COVID-19 will not be successful without Indian vaccine manufacturers. We were the first to produce the vaccination for Covid-19.With this outperformance, many companies turned out to be multi-baggers for the investors.
The company manufactures a wide range of APIs for oral cephalosporins, beta-lactams formulation, Special nutraceuticals, etc. The company is also engaged in formulation development for various segments like anti-oxidants, oral anti-diabetics. The return given by the company is 25,770.64% in one year with 52 weekly low of Rs.17.15 & made a high of Rs.2654.25
The company engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non-Betalactum productsThe return given by the company is 567.32% in one year with 52 weekly low of Rs.20.35 & made a high of Rs.233.55
The company engaged in the manufacturing and supplying of International Quality Formulations and Active Pharmaceutical Ingredients worldwide. The return given by the company is 562.09% in one year with 52 weekly low of Rs.27.05 & made a high of Rs.234
The company manufactures & markets drugs for domestic & international customers, Primarily engaged in the manufacturing of oncology products It includes anti-cancer tablets, Injections & lyophilized injections.The return given by the company is 520.00% in one year with 52 week low of Rs.47. & made a high of Rs.350.20
The company offers an integrated portfolio of API which includes intermediate, generic finished dosage forms and carries out contract research services. The return given by the company is 476.39% in one year with 52 weekly low of Rs.92.80. & made a high of Rs.544.95
The company engaged in the business of manufacturing of formulations Active Pharmaceutical Ingredient(API) and Contract Research and Manufacturing Services.The return given by the company is 425% in one year with 52 weekly low of Rs.19.05 & made a high of Rs.114.00
The Company is a leading manufacturer of active pharmaceutical ingredients & an end-to-end solution provider for the pharmaceutical industry.The return given by the company is 423.19% in one year with 52 weekly low of Rs.387.75 & made a high of Rs.2844.40
The company is pure play for API & engaged in the manufacturing & development of API. It also offers Contract Manufacturing & development services for foreign companies.The return given by the company is 215.97% in one year with 52 week low of Rs.516.35 & made a high of Rs. 1859.95
The company is one of the major pharmaceutical manufacturers in the country. It is engaged in the manufacturing of pharmaceuticals. It also operates in anti-diarrhoea, anti-inflammatory, and anti-biotic therapeutic segments.The return given by the company is 201.72% in one year with a 52 week low of Rs.227.75 & made a high of Rs. 1026.95
Swastika Investmart Ltd. Group : Registered with
SEBI Reg. No. : NSE/BSE/MSEI/MCX/NCDEX: INZ000192732
Merchant Banking : INM000012102
Investment Adviser: INA000009843
CDSL/NSDL : IN-DP-115-2015
RBI Reg. No. : B-03-00174
IRDA Reg. No. : 713
NCDEX : 00844
Online Dispute Resolution : ODR
Issued in the interest of investors: Prevent Unauthorised transactions in your trading and Demat account. Update your mobile numbers/email IDs with Swastika Investmart Ltd.. Receive alerts and information of all debit and other important transactions in your trading and Demat account directly from Exchange/Depository on your mobile/email at the end of the day. KYC is a onetime exercise while dealing in securities markets. Once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. For any grievances or queries related to Swastika Investmart Ltd., please drop an email at email@example.com. To see the investor charter : NSDL- https://nsdl.co.in/publications/investor_charter.php, CDSL- https://www.cdslindia.com/Investors/InvestorCharter.html. You can also register your complaint with NSE - www. nse-investorhelpline.com/NICE PLUS, BSE - firstname.lastname@example.org, MCX - email@example.com, NCDEX - firstname.lastname@example.org, SEBI - scores.gov.in/scores/Welcome.html. Benefits of SEBI SCORES - effective communication, speedy redressal of the grievances.“Attention Investors
.......... Issued in the interest of Investors"
Note: Standard warning- “Investment in securities market are subject to market risks, read all the related documents carefully before investing"
RISK DISCLOSURES ON DERIVATIVES.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Trust Our Expert Picks
for Your Investments!